ELI LILLY AND COMPANY Restricted Cash and Cash Equivalents, Noncurrent
ELI LILLY AND COMPANY (LLY) had Restricted Cash and Cash Equivalents, Noncurrent of $0 as of 2015-12-31, per its 10-K filed 2016-02-19.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:RestrictedCashAndCashEquivalentsNoncurrent · last filed 2018-02-20
- 2015-12-31: Restricted Cash and Cash Equivalents, Noncurrent $0.00.
- 2015-09-30: Restricted Cash and Cash Equivalents, Noncurrent $0.00.
- 2015-06-30: Restricted Cash and Cash Equivalents, Noncurrent $0.00.
- 2015-03-31: Restricted Cash and Cash Equivalents, Noncurrent $0.00.
| Period end | Restricted Cash and Cash Equivalents, Noncurrent | Restricted Cash and Cash Equivalents, Noncurrent as first filed |
|---|---|---|
| 2015-12-31 | $0.00 10-K · filed 2016-02-19 | |
| 2015-09-30 | $0.00 10-Q · filed 2015-10-30 | |
| 2015-06-30 | $0.00 10-Q · filed 2015-07-30 | |
| 2015-03-31 | $0.00 10-Q · filed 2015-04-30 | |
| 2014-12-31 | $5.41B 10-K · filed 2018-02-20 | $5.41B 10-K · filed 2015-02-19 |
| 2013-12-31 | $0.00 10-K · filed 2015-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |